IOL Chemicals and Pharmaceuticals Ltd receives approval from NMPA, China for Clopidogrel Bisulfate API

The Centre for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), China, has approved IOL Chemicals and Pharmaceuticals Limited's API product "Clopidogrel Bisulfate", on 14th July 2026.

This approval is in addition to the valid Certificate of Suitability (CEP) already held by the Company for Clopidogrel Bisulfate, further strengthening the Company's regulatory portfolio and expanding its access to the Chinese pharmaceutical market.

Source : Equity Bulls

Keywords

IOLChemicalsandPharmaceuticals CDE NMPA China Approval API ClopidogrelBisulfate